{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:37:02Z","timestamp":1788878222525,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-1013-32017"],"award-info":[{"award-number":["PB-PG-1013-32017"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3275-x","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T15:04:04Z","timestamp":1555427044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Uro-Vaxom\u00ae versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility study"],"prefix":"10.1186","volume":"20","author":[{"given":"Derick","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7604-0194","authenticated-orcid":false,"given":"James","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadel","family":"Derry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"3275_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/jac\/dkl010","volume":"57","author":"J Salomon","year":"2006","unstructured":"Salomon J, Denys P, Merle C, Chartier-Kastler E, Perronne C, Gaillard JL, Bernard L. Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2-year follow-up\u2014an observational prospective study. J Antimicrob Chemother. 2006;57:784\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"3275_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/nau.21003","volume":"30","author":"A Manack","year":"2011","unstructured":"Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, Jones JK. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30:395\u2013401.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0022-5347(05)67157-1","volume":"164","author":"A Esclarin De Ruz","year":"2000","unstructured":"Esclarin De Ruz A, Garcia Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164:1285\u20139.","journal-title":"J Urol"},{"key":"3275_CR4","first-page":"129","volume":"14","author":"B Khatri","year":"2012","unstructured":"Khatri B, Basnyat S, Karki A, Poudel A, Shrestha B. Etiology and antimicrobial susceptibility pattern of bacterial pathogens from urinary tract infection. Nepal Med Coll J. 2012;14:129\u201332.","journal-title":"Nepal Med Coll J"},{"key":"3275_CR5","first-page":"s191","volume":"19","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:s191\u20136.","journal-title":"Am J Manag Care"},{"key":"3275_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11908-011-0208-6","volume":"13","author":"F D'Hondt","year":"2011","unstructured":"D'Hondt F, Everaert K. Urinary tract infections in patients with spinal cord injuries. Curr Infect Dis Rep. 2011;13:544\u201351.","journal-title":"Curr Infect Dis Rep"},{"key":"3275_CR7","unstructured":"National Institute for Healthcare and Clinical Excellence: Urinary incontinence in neurological disease: assessment and management. \n                    https:\/\/www.nice.org.uk\/guidance\/cg148\n                    \n                  . Accessed 23 Sept 2018."},{"key":"3275_CR8","unstructured":"National Institute for Healthcare and Clinical Excellence: Urinary tract infection (lower) \u2013 women. 2009. \n                    http:\/\/cks.nice.org.uk\/urinary-tract-infection-lower-women\n                    \n                  . Accessed 23 Sept 2018."},{"key":"3275_CR9","unstructured":"National Institute for Healthcare and Clinical Excellence: Urinary tract infection (lower) \u2013 Men. 2010. \n                    https:\/\/www.nice.org.uk\/guidance\/cg97\n                    \n                  . Accessed 23 Sept 2018."},{"key":"3275_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1503\/cmaj.141044","volume":"187","author":"A Salameh","year":"2015","unstructured":"Salameh A, Al Mohajer M, Daroucihe RO. Prevention of urinary tract infections in patients with spinal cord injury. CMAJ. 2015;187:807\u201311.","journal-title":"CMAJ"},{"key":"3275_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sc.2008.25","volume":"46","author":"MJ Hess","year":"2008","unstructured":"Hess MJ, Hess PE, Sullivan MR, Nee M, Yalla SV. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord. 2008;46:622\u20136.","journal-title":"Spinal Cord"},{"key":"3275_CR12","doi-asserted-by":"publisher","first-page":"j5193","DOI":"10.1136\/bmj.j5193","volume":"359","author":"J Barclay","year":"2017","unstructured":"Barclay J, Veeratterapillay R, Harding C. Non-antibiotic options for recurrent urinary tract infections in women. BMJ. 2017;359:j5193.","journal-title":"BMJ"},{"key":"3275_CR13","first-page":"101","volume":"5","author":"M Huber","year":"2000","unstructured":"Huber M, Ayoub M, Pfannes SD, Mittenbuhler K, Weis K, Bessler WG, Baier W. Immunostimulatory activity of the bacterial extract OM-8. Eur J Med Res. 2000;5:101\u20139.","journal-title":"Eur J Med Res"},{"key":"3275_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.eururo.2004.12.009","volume":"47","author":"HW Bauer","year":"2005","unstructured":"Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC. Multicenter UTISG.:A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47:542\u20138 discussion 548.","journal-title":"Eur Urol"},{"key":"3275_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0022-5347(17)35648-3","volume":"150","author":"CC Schulman","year":"1993","unstructured":"Schulman CC, Corbusier A, Michiels H, Taenzer HJ. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993;150:917\u201321.","journal-title":"J Urol"},{"key":"3275_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000475363","volume":"26","author":"P Magasi","year":"1994","unstructured":"Magasi P, Panovics J, Illes A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26:137\u201340.","journal-title":"Eur Urol"},{"key":"3275_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1464-410X.1990.tb14649.x","volume":"65","author":"H Tammen","year":"1990","unstructured":"Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990;65:6\u20139.","journal-title":"Br J Urol"},{"key":"3275_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0022-5347(17)40084-X","volume":"143","author":"HJ Hachen","year":"1990","unstructured":"Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990;143:759\u201362 discussion 762-753.","journal-title":"J Urol"},{"key":"3275_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/nau.23859","volume":"38","author":"Krebs J","year":"2019","unstructured":"Krebs J, Fleischli S, Stoyanov J, Pannek J. Effects of oral immunomodulation therapy on urinary tract infections in individuals with chronic spinal cord injury\u2014A retrospective cohort study. Neurourol Urodyn. 2019;38:346\u201352.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR20","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Medicines for Human Use (Clinical Trials) Regulations. 2004. \n                    http:\/\/www.legislation.gov.uk\/uksi\/2004\/1031\/made\n                    \n                  . Accessed 23 Sept 2018."},{"key":"3275_CR21","doi-asserted-by":"publisher","first-page":"i5239","DOI":"10.1136\/bmj.i5239","volume":"355","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, PAFS Consensus Group. CONSORT 2010 Statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.","journal-title":"BMJ"},{"key":"3275_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.juro.2010.03.024","volume":"184","author":"F Sunden","year":"2010","unstructured":"Sunden F, Hakansson L, Ljunggren E, Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 2010;184:179\u201385.","journal-title":"J. Urol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3275-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T23:23:16Z","timestamp":1586906596000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3275-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3275-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"24 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"National Research Ethics Service London Harrow granted favourable opinion (for the whole study) on 1 March 2016 (reference 15\/LO\/2069). Informed consent will be obtained from patients before participation into the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"223"}}